1-三苯甲基-D-组氨酸甲酯盐酸盐(1:1) | 200927-02-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 中文名称: 1-三苯甲基-D-组氨酸甲酯盐酸盐(1:1)
• 英文名称: (R)-Methyl 2-amino-3-(1-trityl-1H-imidazol-4-yl)propanoate hydrochloride
• 英文别名: methyl (2R)-2-amino-3-(1-tritylimidazol-4-yl)propanoate;hydrochloride
• CAS: 200927-02-2
• 化学式: C26H26ClN3O2
• 分子量: 448.0
• InChiKey: RSIWDQDVADNDKT-GJFSDDNBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.19
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  70.1
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Novel nitrogen-containing heteroaryl compounds and methods of use thereof
  申请人：FibroGen, Inc.

  公开号：US20040254215A1

  公开（公告）日：2004-12-16

  The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.

  本发明涉及适用于介导缺氧诱导因子和治疗与促红细胞生成素相关疾病的化合物，通过在体外和体内增加内源性促红细胞生成素来实现。
• [EN] NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN<br/>[FR] COMPOSES HETEROARYLIQUES CONTENANT DE L'AZOTE ET LEUR UTILISATION DANS L'AUGMENTATION DE L'ERYTHROPOIETINE ENDOGENE
  申请人：FIBROGEN INC

  公开号：WO2004108681A1

  公开（公告）日：2004-12-16

  The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.

  本发明涉及一种适用于介导缺氧诱导因子和治疗与促红细胞生成素相关疾病的化合物，通过在体外和体内增加内源性促红细胞生成素。
• NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Arend Michael P.

  公开号：US20080293763A1

  公开（公告）日：2008-11-27

  The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.

  本发明涉及适用于介导缺氧诱导因子并通过在体内外增加内源性促红细胞生成素来治疗与促红细胞生成素相关的疾病的化合物。
• Novel Nitrogen-Containing Heteroaryl Compounds And Methods of Use Thereof
  申请人：AREND P. Michael

  公开号：US20070185159A1

  公开（公告）日：2007-08-09

  The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.

  本发明涉及适合用于介导缺氧诱导因子和治疗与促红细胞生成素相关疾病的化合物，通过在体外和体内增加内源性促红细胞生成素。
• isoquinoline derivatives AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN
  申请人：Fibrogen, Inc.

  公开号：EP2357175A1

  公开（公告）日：2011-08-17

  The present invention relates to compounds I suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.

  本发明涉及适用于通过增加体外和体内内源性促红细胞生成素来介导缺氧诱导因子和治疗促红细胞生成素相关疾病的化合物 I。